Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

immunoclin corp (IMCL) Snapshot

Open
$4.10
Previous Close
$3.00
Day High
$4.10
Day Low
$3.00
52 Week High
06/2/14 - $5.60
52 Week Low
06/30/14 - $1.45
Market Cap
86.5M
Average Volume 10 Days
42.0
EPS TTM
--
Shares Outstanding
28.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOCLIN CORP (IMCL)

Related News

No related news articles were found.

immunoclin corp (IMCL) Related Businessweek News

No Related Businessweek News Found

immunoclin corp (IMCL) Details

Immunoclin Corporation provides comprehensive, clinical, and basic science research services to pharmaceutical, biotechnology, and food industries. It is involved in the research and development on products, such as MIRA, an algorithm to analyze the multi-variant data to identify people who are at risk of having heart attack; and GARD, a genetic test for multiple genetic polymorphisms associated with increased risk of the most common form of dementia. Immunoclin Corporation is also engaged in the research and development of PRIMALEUKIN, an antibacterial, anti-fungal, and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from, infection; DACTELLIGENCE, a technology and newly patented concept in bio-sensing to challenge detection platforms in multiple diagnostic fields; and GastroWellBeing, an immunological food supplement. The company was formerly known as Pharma Investing News, Inc. and changed its name to Immunoclin Corporation in December 2013. Immunoclin Corporation is headquartered in Beverly Hills, California.

immunoclin corp (IMCL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $20.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $20.0K
Chief Scientific Officer and Director
Total Annual Compensation: --
Management Consultant
Total Annual Compensation: $20.0K
Compensation as of Fiscal Year 2014.

immunoclin corp (IMCL) Key Developments

ImmunoClin Corporation announced delayed 10-Q filing

On 12/15/2014, ImmunoClin Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

ImmunoClin Corporation announced delayed 10-Q filing

On 09/15/2014, ImmunoClin Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

ImmunoClin Corporation Appoints Heinz Ellerbrok to its Scientific Advisory Board

ImmunoClin Corporation announced the appointment of Dr. Heinz Ellerbrok to its Scientific Advisory Board. Dr. Ellerbrok is the deputy head of the Centre for Biological Safety, Robert Koch Institute in Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMCL:US $3.00 USD 0.00

IMCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMCL.
View Industry Companies
 

Industry Analysis

IMCL

Industry Average

Valuation IMCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16,737.8x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17,179.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCLIN CORP, please visit www.pharmainvestingnews.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.